Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338215 | 0.88 | MAPT (0.47) | MAPTNPSR1TLR9TLR7PDGFRB | |
| SCHEMBL29055088 | 0.87 | ENPP1 (0.53) | EGFRSRCKDRENPP1MAPT | |
| SCHEMBL906243 | 0.83 | KIT (0.59) | PDGFRBKIT | |
| SCHEMBL29055063 | 0.78 | KIT (0.55) | PDGFRBKIT | |
| SCHEMBL19385231 | 0.77 | TLR9 (0.62) | MAPTNPSR1TLR9TLR7PDGFRB | |
| SCHEMBL20838522 | 0.75 | TLR9 (0.71) | MAPTNPSR1TLR9TLR7PDGFRB | |
| SCHEMBL20782651 | 0.74 | ENPP1 (0.60) | EGFRSRCKDRENPP1MAPT | |
| SCHEMBL30445864 | 0.74 | ENPP1 (0.60) | EGFRSRCKDRENPP1MAPT | |
| SCHEMBL20838519 | 0.74 | TLR9 (0.72) | TLR9TLR7PDGFRBKIT | |
| SCHEMBL15265722 | 0.73 | EGFR (0.61) | EGFRSRCKDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960580-B2 | Nitrogenous heterocyclic substituted quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1490362-A2 | (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | Millennium Pharmaceuticals, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002072578-A2 | (HOMO) PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | MILLENNIUM PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | WNK2, PDGFA, PDGFRA | EGFR 172/4885SRC 228/4885KDR 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.